PROM1 and acute lymphoblastic leukemia: Based on these results, an additional evaluation in B-ALL appeared warranted, since CD133 is reportedly expressed in 30–40% of ALL cases and constitutes a promising target antigen for B-ALL therapy [22,26,27].